In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

BACKGROUND: Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. OBJECTIVE: The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434...

Descripción completa

Detalles Bibliográficos
Autores principales: Quindós, Guillermo, Miranda-Cadena, Katherine, San-Millán, Rosario, Borroto-Esoda, Katyna, Cantón, Emilia, Linares-Sicilia, María José, Hamprecht, Axel, Montesinos, Isabel, Tortorano, Anna Maria, Prigitano, Anna, Vidal-García, Matxalen, Marcos-Arias, Cristina, Guridi, Andrea, Sanchez-Reus, Ferran, Machuca-Bárcena, Jesús, Rodríguez-Iglesias, Manuel Antonio, Martín-Mazuelos, Estrella, Castro-Méndez, Carmen, López-Soria, Leyre, Ruiz-Gaitán, Alba, Fernandez-Rivero, Marcelo, Lorenzo, Damaris, Capilla, Javier, Rezusta, Antonio, Pemán, Javier, Guarro, Josep, Pereira, Joana, Pais, Célia, Romeo, Orazio, Ezpeleta, Guillermo, Jauregizar, Nerea, Angulo, David, Eraso, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149255/
https://www.ncbi.nlm.nih.gov/pubmed/35651755
http://dx.doi.org/10.3389/fcimb.2022.906563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149255/
https://www.ncbi.nlm.nih.gov/pubmed/35651755
http://dx.doi.org/10.3389/fcimb.2022.906563

Ejemplares similares